Aardvark Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AARD Nasdaq 2834 aardvarktherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aardvark Therapeutics, Inc.

Datadog, Trade Desk upgraded: Wall Street's top analyst calls - Nov 7th, 2025 7:33 am
Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025 - Nov 4th, 2025 10:00 am
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Nov 3rd, 2025 3:55 pm
Aardvark Therapeutics to Present at Upcoming Investor Conferences in November - Nov 3rd, 2025 6:00 am
Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek - Oct 22nd, 2025 6:00 am
Aardvark Therapeutics Expands Phase 3 HERO Trial Eligibility for ARD-101 in Prader-Willi Syndrome After FDA Protocol Alignment - Oct 17th, 2025 7:27 am
Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome - Oct 8th, 2025 6:00 am
Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum - Sep 23rd, 2025 2:05 pm
MapLight lines up an IPO in bid to challenge Bristol Myers schizophrenia drug - Sep 22nd, 2025 6:01 am
Insider Stock Buying Reaches US$730.4k On Aardvark Therapeutics - Sep 22nd, 2025 4:43 am
LB Pharmaceuticals raises $285 million in US IPO - Sep 10th, 2025 7:23 pm
LB Pharmaceuticals eyes $322 million valuation in biotech IPO amid sector drought - Sep 8th, 2025 8:41 am
2 ‘Strong Buy’ Growth Stocks Offering 300% or Higher Upside - Sep 2nd, 2025 5:30 am
Aardvark Therapeutics to Present at Upcoming Investor Conferences in September - Aug 27th, 2025 2:10 pm
Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates - Aug 13th, 2025 2:10 pm
Retail investors among Aardvark Therapeutics, Inc.'s (NASDAQ:AARD) largest stockholders and were hit after last week's 11% price drop - Aug 12th, 2025 12:35 pm
Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy - Aug 12th, 2025 6:00 am
OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company - Jul 15th, 2025 5:30 am
Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress - Jul 1st, 2025 3:31 pm
Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference - Jun 24th, 2025 6:00 am